Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
Shattuck Labs, a biotech company focused on inflammatory and immune-mediated diseases, announced plans to start a Phase 2 clinical trial in 2026 to evaluate its drug candidate SL-325 for moderate to severe hidradenitis suppurativa (HS). The company also appointed Dr. Shoba Ravichandran as Senior Vice President of Clinical Development to lead this p…